In BRCA1/2 mutant cancers that have been treated with PARP inhibitors, increased expression of MDR1 genes have been observed, leading to increased expression of Pgp and a resultant higher rate of drug efflux, diminishing the therapeutic intracellular effect of PARP inhibitors [42]. The gene discussed is BRCA1; the disease is cancer.